HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE
HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), has signed a non-binding term sheet with a global medical device manufacturer for a strategic investment. The deal involves a $2.5 million investment to purchase Series A Convertible Preferred Stock at a $50 million pre-money valuation.
The investment terms include a dividend based on market conditions and the right to appoint a director to HOPE's Board. The pre-money valuation may be adjusted based on EBITDA results for Q3 2026. The funding, combined with expected bank financing and current assets, will support HOPE's recently announced clinic acquisitions.
HOPE Therapeutics aims to establish a network of clinics specializing in treating suicidal depression and PTSD using ketamine, TMS, and other treatment modalities.
HOPE Therapeutics, una controllata interamente di NRx Pharmaceuticals (NASDAQ:NRXP), ha firmato un accordo preliminare non vincolante con un produttore globale di dispositivi medici per un investimento strategico. L'accordo prevede un investimento di 2,5 milioni di dollari per l'acquisto di azioni privilegiate convertibili di Serie A a una valutazione pre-money di 50 milioni di dollari.
I termini dell'investimento includono un dividendo basato sulle condizioni di mercato e il diritto di nominare un direttore nel Consiglio di HOPE. La valutazione pre-money potrebbe essere regolata in base ai risultati EBITDA per il terzo trimestre del 2026. Il finanziamento, combinato con il previsto finanziamento bancario e gli attuali attivi, supporterà le recenti acquisizioni di cliniche annunciate da HOPE.
HOPE Therapeutics mira a stabilire una rete di cliniche specializzate nel trattamento della depressione suicidaria e del PTSD utilizzando ketamina, TMS e altre modalità di trattamento.
HOPE Therapeutics, una subsidiaria de propiedad total de NRx Pharmaceuticals (NASDAQ:NRXP), ha firmado un acuerdo de términos no vinculante con un fabricante global de dispositivos médicos para una inversión estratégica. El acuerdo implica una inversión de 2.5 millones de dólares para la compra de acciones preferentes convertibles de la Serie A a una valoración pre-money de 50 millones de dólares.
Los términos de la inversión incluyen un dividendo basado en las condiciones del mercado y el derecho a nombrar un director en la Junta de HOPE. La valoración pre-money puede ser ajustada en función de los resultados de EBITDA para el tercer trimestre de 2026. La financiación, combinada con la financiación bancaria esperada y los activos actuales, apoyará las recientes adquisiciones de clínicas anunciadas por HOPE.
HOPE Therapeutics tiene como objetivo establecer una red de clínicas especializadas en el tratamiento de la depresión suicida y el PTSD utilizando ketamina, TMS y otras modalidades de tratamiento.
HOPE Therapeutics는 NRx Pharmaceuticals (NASDAQ:NRXP)의 완전 자회사로, 글로벌 의료기기 제조업체와 전략적 투자에 대한 비구속적 조건 시트를 체결했습니다. 이 거래는 2.5백만 달러의 투자를 포함하여 5천만 달러의 프리머니 가치로 시리즈 A 전환 우선주를 구매하는 것입니다.
투자 조건에는 시장 상황에 따른 배당금과 HOPE 이사회에 이사를 임명할 권리가 포함됩니다. 프리머니 가치는 2026년 3분기 EBITDA 결과에 따라 조정될 수 있습니다. 이 자금은 예상되는 은행 금융 및 현재 자산과 결합되어 HOPE가 최근 발표한 클리닉 인수 지원에 사용될 것입니다.
HOPE Therapeutics는 케타민, TMS 및 기타 치료 방법을 사용하여 자살 우울증 및 PTSD 치료를 전문으로 하는 클리닉 네트워크를 구축하는 것을 목표로 하고 있습니다.
HOPE Therapeutics, une filiale entièrement détenue de NRx Pharmaceuticals (NASDAQ:NRXP), a signé une feuille de conditions non contraignante avec un fabricant mondial de dispositifs médicaux pour un investissement stratégique. L'accord implique un investissement de 2,5 millions de dollars pour l'achat d'actions privilégiées convertibles de série A à une valorisation pré-money de 50 millions de dollars.
Les conditions de l'investissement incluent un dividende basé sur les conditions du marché et le droit de nommer un directeur au conseil d'administration de HOPE. La valorisation pré-money peut être ajustée en fonction des résultats de l'EBITDA pour le troisième trimestre 2026. Le financement, combiné avec le financement bancaire prévu et les actifs actuels, soutiendra les récentes acquisitions de cliniques annoncées par HOPE.
HOPE Therapeutics vise à établir un réseau de cliniques spécialisées dans le traitement de la dépression suicidaire et du PTSD en utilisant la kétamine, le TMS et d'autres modalités de traitement.
HOPE Therapeutics, eine hundertprozentige Tochtergesellschaft von NRx Pharmaceuticals (NASDAQ:NRXP), hat ein nicht verbindliches Term Sheet mit einem globalen Hersteller von Medizinprodukten für eine strategische Investition unterzeichnet. Der Deal umfasst eine Investition von 2,5 Millionen Dollar zum Kauf von Serie-A-wandelbaren Vorzugsaktien zu einer Pre-Money-Bewertung von 50 Millionen Dollar.
Die Investitionsbedingungen beinhalten eine Dividende, die von den Marktbedingungen abhängt, sowie das Recht, einen Direktor in den Vorstand von HOPE zu berufen. Die Pre-Money-Bewertung kann basierend auf den EBITDA-Ergebnissen für das dritte Quartal 2026 angepasst werden. Die Finanzierung, kombiniert mit der erwarteten Bankenfinanzierung und den aktuellen Vermögenswerten, wird die kürzlich angekündigten Klinikübernahmen von HOPE unterstützen.
HOPE Therapeutics hat das Ziel, ein Netzwerk von Kliniken aufzubauen, die sich auf die Behandlung von suizidaler Depression und PTSD mit Ketamin, TMS und anderen Behandlungsmodalitäten spezialisiert haben.
- Strategic investment of $2.5M from global medical device manufacturer
- $50M pre-money valuation for HOPE Therapeutics
- Additional funding expected through bank financing
- Expansion through acquisition of profitable existing clinics
- Term sheet is non-binding and subject to definitive agreement
- Pre-money valuation subject to future adjustment based on Q3 2026 EBITDA
Insights
This term sheet represents a notable moment for NRx Pharmaceuticals, with its wholly-owned subsidiary HOPE Therapeutics securing a non-binding term sheet for a
The proposed investment structure through Series A Convertible Preferred Stock includes dividend rights and board representation for the unnamed medical device manufacturer, suggesting a strategic rather than purely financial investment. The valuation adjustment mechanism tied to Q3 2026 EBITDA introduces considerable contingent risk if performance targets aren't met.
While external validation from a global industry player adds credibility to HOPE's clinic acquisition strategy, investors should note several cautionary elements: the modest investment amount (
This transaction creates strategic questions about how NRx plans to maximize shareholder value from HOPE's apparently underrecognized value - through continued ownership or potential future spin-off. The market will likely want additional details on definitive agreement timing and the strategic rationale for both parties.
HOPE Therapeutics is positioning itself in the rapidly evolving interventional psychiatry space, focusing on ketamine, TMS, and other modalities for treatment-resistant depression and PTSD. Their acquisition-based growth strategy targeting "already-profitable, best-in-class" clinics is a pragmatic approach that potentially reduces operational risk while creating scale challenges.
The strategic investment from a medical device manufacturer suggests potential equipment synergies - likely involving transcranial magnetic stimulation (TMS) or other interventional technologies. This manufacturing partner could accelerate HOPE's technology implementation across acquired clinics while potentially securing a distribution channel for their devices.
From a market perspective, HOPE is targeting a genuine unmet need. Approximately
The business model of consolidating profitable clinics could create economies of scale in equipment purchasing, administrative functions, and marketing. However, integration challenges remain significant in healthcare services, where practitioner relationships and local market dynamics heavily influence success. While the investment provides validation, HOPE faces substantial execution risks in its roll-up strategy amid intensifying competition in the mental health treatment space.
- Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities
The Term Sheet, which is non-binding and subject to the execution of a definitive Stock Purchase Agreement, contemplates an investment of
This investment, together with expected bank financing and current balance sheet assets, is anticipated to close concurrent with, and in support of, the closing of HOPE's recently announced clinic acquisitions.
"As identified in our recent annual report and in recently published independent research reports, we continue to execute on our strategy to combine already-profitable, best-in-class interventional psychiatry clinics to serve the extraordinary unmet need of patients with severe depression and PTSD," said Jonathan Javitt, MD, MPH, and Matthew Duffy, co-CEO's of HOPE Therapeutics.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company currently developing a best-in-class network of interventional psychiatry clinics to offer psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other lifesaving, neuroplastic therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under data sharing agreements. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima, Neurospa and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
Chief Business Officer, NRx Pharmaceuticals, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-a-term-sheet-for-strategic-investment-from-a-global-medical-device-manufacturer-into-hope-302419478.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the size of the strategic investment in HOPE Therapeutics (NRXP)?
How will HOPE Therapeutics (NRXP) use the new investment funding?
What treatment methods will HOPE Therapeutics' clinics offer?
What rights does the Series A Preferred Stock investment in NRXP's HOPE Therapeutics include?
